Drug Profile
RL 315535
Alternative Names: LY 315535Latest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Unknown
- Developer Shire Pharmaceuticals Group
- Class Irritable bowel syndrome therapies
- Mechanism of Action 5-HT1A serotonin receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Irritable bowel syndrome; Non-ulcer dyspepsia
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 21 Jun 2000 RL 315535 is available for licensing (http://www.shire.com)
- 27 Mar 2000 Discontinued-I for Irritable bowel syndrome in USA (PO)